Altaris Capital completed the acquisition of Intricon for $241m.

Altaris Capital, an investment firm, completed the acquisition of Intricon, an international company and joint development manufacturer of micromedical components, sub-assemblies and final devices, for $241m. “We are excited to enter into this transaction with Altaris, which will deliver a compelling valuation to our shareholders and enable us to accelerate the advancement of our joint development manufacturing capabilities in micromedical technology across a broad range of high growth markets. Our team has done an outstanding job of establishing Intricon as the partner of choice for companies that are bringing truly advanced technology to medical devices. As we enter the next chapter for our company, we believe that Altaris is the ideal partner to help us further advance our mission," Scott Longval, Intricon President and CEO.